In a report released today, Peter Lawson from Barclays maintained a Buy rating on Bicycle Therapeutics (BCYC – Research Report), with a price target of $40.00. The company’s shares closed yesterday at $24.69.
According to TipRanks, Lawson is a 4-star analyst with an average return of 7.2% and a 44.47% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Biomea Fusion, and Exelixis.
Currently, the analyst consensus on Bicycle Therapeutics is a Strong Buy with an average price target of $44.71, an 81.09% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $55.00 price target.
BCYC market cap is currently $1.03B and has a P/E ratio of -4.70.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BCYC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bicycle Therapeutics (BCYC) Company Description:
Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
